Susanna Juteau

Susanna Juteau

Auto-generated profile, based on publicly available information

Susanna Juteau

Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2024 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
SPSanteri A. Pakola
Santeri A. Pakola
KPKatriina J. Peltola
Katriina J. Peltola
JCJames H.A. Clubb
James H.A. Clubb
EJElise Jirovec
Elise Jirovec
LHLyna Haybout
Lyna Haybout
AHAkseli Hemminki
Akseli Hemminki
Purpose: TILT-123 (igrelimogene litadenorepvec) is an oncolytic adenovirus armed with TNFa and IL2, designed to induce T-cell infiltration and cytotoxicity in solid tumors. Patients and Methods: TUNIMO (NCT04695327) was a single-arm, multicenter phase I dose-escalation trial designed to assess the safety of TILT-123 in advanced solid cancers refractory to standard therapy. Patients received intravenous and intratumoral TILT-123. The primary endpoint was safety by adverse events (AE), laboratory values, vital signs, and electrocardiograms. Secondary endpoints included tumor response, pharmacokinetics, and predictive biomarkers. Results: Twenty patients were enrolled, with a median age of 58 years. Most prevalent cancer types included sarcomas (35%), melanomas (15%) and ovarian cancers (15%). No dose-limiting toxicities were observed. The most frequent treatment-related AEs included fever (16.7%), chills (13.0%), and fatigue (9.3%). Ten patients were evaluable for response on day 78 with RECIST 1.1, iRECIST or PET-based evaluation. The disease control rate by PET was 6/10 (60% of evaluable patients) and 2/10 by RECIST 1.1 and iRECIST(20%of evaluable patients). Tumor size reductions occurred in both injected and non-injected lesions. TILT-123 was detected in injected and non-injected tumors, and virus was observed in blood after intravenous and intratumoral injections. Treatment resulted in reduction of lymphocytes in blood, with concurrent lymphocyte increases in tumors, findings compatible with trafficking. Conclusions: TILT-123 was safe and able to produce antitumor effects in local and distant lesions in heavily pre-treated patients. Good tolerability of TILT-123 facilitates combination studies, several of which are ongoing (NCT04217473, NCT05271318, NCT05222932, and NCT06125197). See related commentary by Silva-Pilipich and Smerdou, p. 3649

17 January 2022 in Annals of Medicine
Verified
Journal Article
Open access
EREmma K. Rousi
Emma K. Rousi
RKRoope A. Kallionpää
Roope A. Kallionpää
RKRoosa E. Kallionpää
Roosa E. Kallionpää
SJSusanna M. Juteau
Susanna M. Juteau
LTLauri A. I. Talve
Lauri A. I. Talve
IKIlkka O. Koskivuo
Ilkka O. Koskivuo
Changes in the incidence of melanoma in children and adolescents have been reported in Europe and in the USA in the recent decades.The aim of this study was to examine the incidence of paediatric a...

9 January 2024 in JCI Insight
Verified
Journal Article
Open access
PDF file
SASanni Alve
Sanni Alve
SGSilvia Gramolelli
Silvia Gramolelli
JJJoonas Jukonen
Joonas Jukonen
SJSusanna Juteau
Susanna Juteau
APAnne Pink
Anne Pink
POPäivi Ojala
Päivi Ojala
Despite strong indications that interactions between melanoma and lymphatic vessels actively promote melanoma progression, the molecular mechanisms are not yet completely understood. To characterize molecular factors of this crosstalk, we established human primary lymphatic endothelial cell (LEC) cocultures with human melanoma cell lines. Here, we show that coculture with melanoma cells induced transcriptomic changes in LECs and led to multiple changes in their function. WNT5B, a paracrine signaling molecule upregulated in melanoma cells upon LEC interaction, was found to contribute to the functional changes in LECs. Moreover, WNT5B transcription was regulated by Notch3 in melanoma cells following the coculture with LECs, and Notch3 and WNT5B were coexpressed in melanoma patient primary tumor and metastasis samples. Moreover, melanoma cells derived from LEC coculture escaped efficiently from the primary site to the proximal tumor-draining lymph nodes, which was impaired upon WNT5B depletion. This supported the role of WNT5B in promoting the metastatic potential of melanoma cells through its effects on LECs. Finally, DLL4, a Notch ligand expressed in LECs, was identified as an upstream inducer of the Notch3/WNT5B axis in melanoma. This study elucidated WNT5B as a key molecular factor mediating bidirectional crosstalk between melanoma cells and lymphatic endothelium and promoting melanoma metastasis.

31 January 2020 in Acta Oncologica
Verified
Journal Article
Closed access
SMSiru Mäkelä
Siru Mäkelä
LKLaura Kohtamäki
Laura Kohtamäki
MLMarjut Laukka
Marjut Laukka
SJSusanna Juteau
Susanna Juteau
MHMicaela Hernberg
Micaela Hernberg
Purpose: To date, no clinical study has reported on the optimal treatment duration of PD-1 blockade in patients with metastatic melanoma. Worldwide, concern has been expressed that due to the high cost of anti-PD-1 therapy, it is not available for all patients. After approval of anti-PD-1 therapy as a first-line treatment, the Helsinki University Hospital institutional board for new drugs decided to treat the first patient cohort within a limited treatment duration program in order to offer this treatment to as many patients as possible. Patients and methods: The first 40 patients with metastatic melanoma initiating treatment at Helsinki University Hospital were to be treated within a six months maximum limited duration program. Patient follow-up was systematic according to a prospectively planned treatment protocol to enable evaluation of treatment efficacy and the safety of this treatment approach. Results: Thirty-eight patients were treated within the program. Seventeen out of these 38 patients completed the six-month regimen. Five discontinued treatment early due to toxicity, and 16 discontinued due to progressive disease. The response rate (RR) for all patients was 39%, but only 33% of these responses are ongoing. Median progression-free survival (PFS) for patients who completed the six-month therapy was 12 months (range, two to 44 months), and median overall survival (OS) has not yet been reached. Conclusions: Although RR is comparable to published data, the response duration is shorter. Based on our results, limiting treatment to only six months may increase the risk of shortening response duration.

30 June 2024 in Oral Diseases
Verified
Journal Article
Closed access
DFDaniel Lobato Ferreira Ferraz
Daniel Lobato Ferreira Ferraz
ESErison Santana dos Santos
Erison Santana dos Santos
CPCaique Mariano Pedroso
Caique Mariano Pedroso
BSBrunno Santos de Freitas Silva
Brunno Santos de Freitas Silva
Omar KujanOmar Kujan
Omar Kujan
Alan Roger Santos-SilvaAlan Roger Santos-Silva
Alan Roger Santos-Silva

23 July 2025 in Pigment Cell & Melanoma Research
Verified
Journal Article
Open access
PDF file
STSanni K. A. Tulokas
Sanni K. A. Tulokas
SJSusanna Juteau
Susanna Juteau
SMSiru P. Mäkelä
Siru P. Mäkelä
KVKatja E. Välimäki
Katja E. Välimäki
TPTeijo Pellinen
Teijo Pellinen
MHMicaela M. Hernberg
Micaela M. Hernberg
As effective melanoma treatments have become available, utilizing isolated limb perfusion (ILP) to treat unresectable melanoma limited to the limb has decreased. However, some patients still receive long‐term benefits from ILP. We aimed to identify features of the pretreatment tumor microenvironment (TME) to identify patients who may benefit from ILP. Pretreatment metastatic melanoma samples from 22 patients treated at Helsinki University Hospital with ILP from 2008 to 2018 were analyzed with multiplex immunohistochemistry (mIHC) and digital image analysis. Antibody panels evaluated the proportions of immune cells in the intratumoral and extratumoral compartments. We examined whether treatment response and median progression‐free survival (PFS) after ILP correlated to findings in the TME. A statistically significant positive correlation was found between PFS and lower immune cell infiltrations in the intratumoral compartment (CD3+, CD4+, and CD11c+ cells), and increased numbers of immune cells in the extratumoral compartment were associated with longer PFS (CD3+, CD4+, CD8+, all expressing PD‐1). Furthermore, the distribution of some immune cell subsets correlated with complete treatment response (PD‐1/PD‐L1‐positive CD4+ and PD‐1‐positive CD8+ cells). Our results suggest that patients may have a better ILP outcome if the metastases exhibit a lower distribution of specific immune cell subtypes intratumorally and a higher extratumoral distribution of some immune cell subtypes.